company background image
SCYX

SCYNEXIS NasdaqGM:SCYX Stock Report

Last Price

US$1.82

Market Cap

US$59.4m

7D

-23.5%

1Y

-74.7%

Updated

06 Dec, 2022

Data

Company Financials +
SCYX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SCYX Stock Overview

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States.

SCYNEXIS, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SCYNEXIS
Historical stock prices
Current Share PriceUS$1.82
52 Week HighUS$7.58
52 Week LowUS$1.70
Beta1.81
1 Month Change-18.39%
3 Month Change-25.10%
1 Year Change-74.69%
3 Year Change-77.93%
5 Year Change-91.91%
Change since IPO-97.98%

Recent News & Updates

Recent updates

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15
Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like

Feb 01
Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like

Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares

Dec 28
Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares

SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?

Dec 15
SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?

Shareholder Returns

SCYXUS PharmaceuticalsUS Market
7D-23.5%1.5%1.1%
1Y-74.7%15.0%-17.6%

Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 15% over the past year.

Return vs Market: SCYX underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is SCYX's price volatile compared to industry and market?
SCYX volatility
SCYX Average Weekly Movement11.4%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: SCYX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: SCYX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199956Marco Tagliettihttps://www.scynexis.com

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).

SCYNEXIS, Inc. Fundamentals Summary

How do SCYNEXIS's earnings and revenue compare to its market cap?
SCYX fundamental statistics
Market CapUS$59.44m
Earnings (TTM)-US$77.62m
Revenue (TTM)US$4.16m

14.3x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SCYX income statement (TTM)
RevenueUS$4.16m
Cost of RevenueUS$599.00k
Gross ProfitUS$3.57m
Other ExpensesUS$81.19m
Earnings-US$77.62m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.38
Gross Margin85.61%
Net Profit Margin-1,864.15%
Debt/Equity Ratio261.2%

How did SCYX perform over the long term?

See historical performance and comparison